Cardiff Oncology's Promising Cancer Breakthrough Ahead—Why I Choose To Buy (CRDF)

Cardiff Oncology, Inc. (NASDAQ: CRDF ) stock is having a tough year after dropping by mid-double-digit losses. However, for the past month it has seen some late single-digit wins as we head towards its Q3 2025 earnings call, which IGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gam ...